{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 458270096
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = u
| target = [[CD40]]
<!-- Clinical data -->
| tradename =  
| pregnancy_category =  
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 903512-50-5
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = P0EP9VFC4R
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08942
<!-- Chemical data -->
| chemical_formula =  
| molecular_weight = 146 kg/mol
}}

'''Lucatumumab''' (CHIR 12.12 or HCD122)<ref name=Hassan2014rev>{{cite journal|last1=Hassan|first1=SB|last2=Sørensen|first2=JF|last3=Olsen|first3=BN|last4=Pedersen|first4=AE|title=Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials.|journal=Immunopharmacology and immunotoxicology|date=April 2014|volume=36|issue=2|pages=96-104|doi=10.3109/08923973.2014.890626|pmid=24555495}}</ref> is a [[human]] [[monoclonal antibody]] against [[CD40]]<ref>[https://web.archive.org/web/20110604012853/http://www.ama-assn.org/ama1/pub/upload/mm/365/lucatumumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council – Lucatumumab], ''American Medical Association''.</ref> development of which was discontinued by [[Novartis]] in 2013 after it was investigated for the treatment of various types of [[cancer]] like [[multiple myeloma]] and [[follicular lymphoma]].<ref>{{cite web|title=Lucatumumab|url=http://adisinsight.springer.com/drugs/800013077|publisher=AdisInsight|accessdate=20 February 2017|language=en}}</ref>  

It is an antagonist to CD40 that was created by scientists at [[Chiron Corporation|Chiron]] using Abgenix' XenoMouse [[transgenic mouse]] to generate fully human antibodies.<ref>{{cite web|title=Press release: XOMA and Chiron Announce Preclinical Data Presentations on CHIR-12.12 at American Hematology Conference|url=http://www.businesswire.com/news/home/20041202005701/en/XOMA-Chiron-Announce-Preclinical-Data-Presentations-CHIR-12.12|publisher=XOMA and Chiron vis Businesswire|language=en|date=December 2, 2004}}</ref><ref>{{cite journal|last1=Weng|first1=Wen-Kai|last2=Tong|first2=Xia|last3=Luqman|first3=Mohammad|last4=Levy|first4=Ronald|title=(Poster Session No. 627-II) A Fully Human Anti-CD40 Antagonistic Antibody, CHIR-12.12, Inhibit the Proliferation of Human B Cell Non-Hodgkin’s Lymphoma.|journal=Blood|date=16 November 2004|volume=104|issue=11|pages=3279–3279|url=http://www.bloodjournal.org/content/104/11/3279|language=en|issn=0006-4971}}</ref>  It was made part of the collaboration between Chiron and Xoma that the companies commenced in 2004.<ref>{{cite news|title=Chiron and Xoma in MAb deal - Pharmaceutical industry news|url=http://www.thepharmaletter.com/article/chiron-and-xoma-in-mab-deal|work=The Pharma Letter|date=March 8, 2004|language=en}}.  Part of Xoma's 10-K filed 2004-03-15.  [https://www.sec.gov/Archives/edgar/data/791908/000119312504042254/0001193125-04-042254-index.htm Index page] at SEC Edgar. </ref><ref>{{cite web|title=Exhibit 10.50: Agreement, dated Feb 27, 2004, by and btwn Chiron Corp and XOMA|url=https://www.sec.gov/Archives/edgar/data/791908/000119312504042254/dex1050.htm|publisher=Xoma via SEC Edgar}}</ref><ref>{{cite web|title=Exhibit 10.2 Amended Research, Development and Commercialization Agreement|url=https://www.sec.gov/Archives/edgar/data/791908/000119312505160702/dex102.htm|website=www.sec.gov|publisher=Xoma via SEC Edgar|date=May 26, 2005}}</ref> Novartis took over the project when it acquired Chiron in 2005.<ref>{{cite news|last1=Tansey|first1=Bernadette|title=Novartis to buy Chiron / Swiss pharmaceutical giant to pay $5.1 billion|url=http://www.sfgate.com/business/article/Novartis-to-buy-Chiron-Swiss-pharmaceutical-2598690.php|work=San Francisco Chronicle|date=November 1, 2005}}</ref><ref>{{cite web|title=Press Release: XOMA Restructures Drug Development Collaboration Including Oncology Drug Candidate HCD122 (NASDAQ:XOMA)|url=http://investors.xoma.com/releasedetail.cfm?ReleaseID=346609|publisher=Xoma|language=en|date=November 10, 2008}}</ref>

In ''in vitro'' studies, it inhibited cell proliferation induced by CD40 ligands and induced cell [[lysis]].<ref>{{cite web|title=NCI Drug Dictionary: lucatumumab|url=https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=432936|publisher=National Cancer Institute|accessdate=20 February 2017|language=en}}</ref>

Over three Phase 1 trials in multiple myeloma and chronic lymphocytic leukemia, the companies made an effort to determine the optimal dose, and obtained unclear results.<ref name=Hassan2014rev/> The Phase I part of a planned Phase I/II trial in multiple myeloma was started in 2005, and in 2012 was updated to Phase II and closed; as of 2014 the results had not been published.<ref name=Hassan2014rev>{{cite journal|last1=Hassan|first1=SB|last2=Sørensen|first2=JF|last3=Olsen|first3=BN|last4=Pedersen|first4=AE|title=Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials.|journal=Immunopharmacology and immunotoxicology|date=April 2014|volume=36|issue=2|pages=96-104|doi=10.3109/08923973.2014.890626|pmid=24555495}}</ref>

== References ==
<references/>

{{Monoclonals for tumors}}

[[Category:Monoclonal antibodies for tumors]]
[[Category:Novartis]]
[[Category:Abandoned drugs]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}